Discover
BCRX
BioCryst Pharmaceuticals, Inc.
9.65
1 x 8.35
1 x 11.18
bid
ask
-
0.35
3.50%
1 @ 04:00 PM
9.77 +0.12 (1.24%)
| Ytd | 23.72% | |
| 1y | 7.22% |
9.59
day range
10.15
6.00
52 week range
10.94
| Open | 10.15 | Prev Close | 10.00 | Low | 9.59 | High | 10.15 | Mkt Cap | 2.45B |
| Vol | 4.83M | Avg Vol | 4.99M | EPS | -1.77 | P/E | N/A | Forward P/E | 14.19 |
| Beta | 0.56 | Short Ratio | 10.68 | Inst. Own | 101.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-03 | 50-d Avg | 8.94 | 200-d Avg | 8.00 | 1yr Est | 21.30 |
BCRX News
benzinga.com
HC Wainwright & Co. Maintains Buy on BioCryst Pharma, Maintains $32 Price Target
HC Wainwright & Co. analyst Andrew S. Fein maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy
benzinga.com
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Cana
benzinga.com
Cantor Fitzgerald Maintains Overweight on BioCryst Pharma, Raises Price Target to $29
Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ:BCRX) with a Overwei
reuters.com
BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs
BioCryst Pharmaceuticals said on Monday it would wind down its internal drug discovery programs and
benzinga.com
BioCryst Shifts Pipeline Strategy, Reaffirms Sales Outlook Of $635.00M-$660.00M Vs 670.47M
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst" or the "Company") today ann
globenewswire.com
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Progr
—Advances strategic shift toward a disciplined research model prioritizing external innovation to ac